Oxford Biomedica bags Novartis leukaemia deal

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

The deal, which is worth between £2.5m and £4.0m to Oxford Biomedica over the next 12 months, will see the Oxford company's LentiVector gene delivery technology manufacture clinical grade genetic material for Novartis's CTL019 clinical development programme.

CTL019 is the lead project in a leukaemia-focused collaboration between the Swiss 'big pharma' player and the University of Pennsylvania.

CTL019 uses a gene delivery system called a lentiviral vector to genetically modify a patient's immune cells before they are re-infused into patients.

According to Edison Investment Research, such 'ex vivo' techniques "are typically difficult to scale-up easily and the deal helps validate Oxford BioMedica's viral vector production expertise".

"Additionally, it also highlights that gene therapy has the potential to dramatically alter life-threatening and severely debilitating disease outcomes."

Oxford BioMedica's Chief Executive Officer John Dawson said: "The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise."

Edison notes that the Novartis payments should mean that the company, which had net cash at end-2012 of £14.1m and is estimated to be burning cash at around £1.0m per month, has enough cash to reach the second quarter of 2014.

Shares in Oxford Biomedica were up 15% at 1.9p by 09:49 on the morning of the announcement.

OH

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Oil producers are back at their Covid-19 lows – is it time to buy?
Oil

Oil producers are back at their Covid-19 lows – is it time to buy?

With demand for oil hammered by Covid-19 and talk of “peak oil demand”, there are lots of good reasons to be bearish on oil producers. So, asks John S…
22 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020
IAG's share price is ready for take-off - here's how to play it
Trading

IAG's share price is ready for take-off - here's how to play it

The owner of British Airways has had a turbulent year, but is now worth a punt. Matthew Partridge explains the best way to play it.
8 Sep 2020